Insights
Search Results
Client Highlights
10.06.26
Firm Advises Alector on Exclusive Global License Agreement with Genentech
On October 5, 2026, Alector, a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, announced it has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, granting Genentech worldwide rights to develop and commercialize Alector’s AL050 program, its brain-penetrant engineered glucocerebrosidase (GCase) ERT. Under the terms of the agreement, Alector will receive an upfront payment of $100 million and is also eligible to receive tiered royalties on net sales and additional payments of up to $1.17 billion upon the achievement of development, regulatory, and commercial milestones. Wilson Sonsini Goodrich & Rosati advised Alector on the transaction.
Client Highlights
10.01.26
Wilson Sonsini Advises Stripe on Acquisition of Parafin
On September 30, 2026, Stripe, the programmable financial services company, announced that it has agreed to acquire Parafin, a leading embedded financial products platform. Wilson Sonsini Goodrich & Rosati is advising Stripe on the transaction.
Client Highlights
9.21.26
Firm Advises CoVet on Acquisition by IDEXX
On September 16, 2026, IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. The financial terms of the transaction were not disclosed. Wilson Sonsini Goodrich & Rosati advised CoVet on the transaction.
CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians’ time. The acquisition expands the value of IDEXX’s software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems.
The Wilson Sonsini team that advised CoVet on the transaction included:
CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians’ time. The acquisition expands the value of IDEXX’s software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems.
The Wilson Sonsini team that advised CoVet on the transaction included:
Client Highlights
9.18.26
Wilson Sonsini Advises Superhuman on Acquisition of Fathom
On September 14, 2026, Superhuman, an AI productivity platform bringing AI to wherever people work, announced its acquisition of Fathom, an AI meeting partner trusted by hundreds of thousands of companies to capture, search, and act on what happens in meetings. Wilson Sonsini Goodrich & Rosati advised Superhuman on the transaction.
Client Highlights
9.10.26
Wilson Sonsini Advises Autodesk on $1 Billion Senior Notes Offering
On September 10, 2026, Autodesk, Inc., completed its offering of $500 million aggregate principal amount of 5.050 percent senior notes due 2029 and $500 million aggregate principal amount of 5.650 percent senior notes due 2033 (together, the “Notes”). Autodesk intends to use the net proceeds from the sale of the Notes, together with cash on hand, to repay $1 billion aggregate principal amount under its existing term loan credit agreement. Wilson Sonsini Goodrich & Rosati advised Autodesk on the transaction.
Client Highlights
9.10.26
Wilson Sonsini Advises Copart on Acquisition of ACV
On September 10, 2026, Copart, Inc., a global leader in online vehicle auctions, and ACV, a leading digital automotive marketplace and data services partner for dealers and commercial clients, announced a definitive agreement in which Copart will acquire all outstanding shares of ACV common stock, valued at approximately $1.9 billion. Wilson Sonsini Goodrich & Rosati advised Copart on the transaction.
Client Highlights
9.03.26
Wilson Sonsini Advises Hugging Face on $12.9 Billion Acquisition by NVIDIA
On September 3, 2026, NVIDIA announced that it has agreed to acquire open-source AI platform Hugging Face for $12.9 billion. Together, NVIDIA and Hugging Face plan to scale Hugging Face’s platform, strengthen its infrastructure, and expand access to AI for developers and institutions worldwide. Wilson Sonsini Goodrich & Rosati advised Hugging Face on the transaction.
Client Highlights
8.25.26
Wilson Sonsini Advises Checkr on Acquisition of Truv
On August 18, 2026, Checkr, an AI-powered verification platform for high-stakes decisions, announced the acquisition of Truv, a consumer-permissioned income, employment, and asset verification company. Wilson Sonsini Goodrich & Rosati advised Checkr on the transaction.
Client Highlights
8.20.26
Wilson Sonsini Advises Homeward Health on Acquisition by Cityblock Health
On August 20, 2026, Cityblock Health announced a definitive agreement to acquire Homeward Health in an all-stock transaction. Wilson Sonsini Goodrich & Rosati advised Homeward Health on the transaction.
Client Highlights
8.05.26
Firm Advises DISA Technologies on Launch of DISA Uranium Corporation
On August 4, 2026, DISA® Technologies, a uranium recovery and production company, announced the formation of DISA Uranium™ Corporation, a new American company built to recover and produce domestic uranium and remediate the nation's legacy uranium sites. In connection with its launch, DISA Uranium has entered into a definitive agreement to acquire IsoEnergy's Utah uranium portfolio of permitted, past-producing mines and projects—giving DISA Uranium a scaled conventional resource base to pair with its proprietary processing technology and the only U.S. Nuclear Regulatory Commission license of its kind. Wilson Sonsini Goodrich & Rosati advised DISA on the transaction.
Client Highlights
6.16.26
Firm Advises 4E Therapeutics on Acquisition by Eli Lilly
On June 16, 2026, 4E Therapeutics, an Austin-based neuroscience company developing next-generation treatments for chronic pain, announced that it has been acquired by Eli Lilly and Company. Wilson Sonsini Goodrich & Rosati advised 4E Therapeutics on the transaction.
Client Highlights
6.10.26
Wilson Sonsini Advises Kiavi on $717 Million Acquisition by Figure
On June 10, 2026, Figure Technology Solutions (Figure), the blockchain-native capital marketplace for the origination, funding, sale, and trading of tokenized assets, announced a definitive agreement to acquire Kiavi, an AI-powered lending platform for residential real estate investors. The transaction includes the purchase of Kiavi’s balance sheet assets by a joint venture between Figure and Sixth Street, a leading global investment firm, who is buying loans off Kiavi’s balance sheet. The total transaction purchase price is $717 million. Wilson Sonsini Goodrich & Rosati is advising Kiavi on the transaction.